Semin Respir Crit Care Med 2016; 37(03): 457-467
DOI: 10.1055/s-0036-1580690
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Diffuse Cystic Lung Diseases: Diagnostic Considerations

Kai-Feng Xu
1   Department of Respiratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
,
Ruie Feng
2   Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
,
Han Cui
1   Department of Respiratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
,
Xinlun Tian
1   Department of Respiratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
,
Hanping Wang
1   Department of Respiratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
,
Jing Zhao
1   Department of Respiratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
,
Hui Huang
1   Department of Respiratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
,
Weihong Zhang
3   Department of Radiology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
,
Bee Hong Lo
4   Developmental Pediatrician, PECAT, Children's Hospital Westmead, Sydney, New South Wales, Australia
› Author Affiliations
Further Information

Publication History

Publication Date:
27 May 2016 (online)

Abstract

Diffuse cystic lung disease (DCLD) is a group of heterogeneous diseases that present as diffuse cystic changes in the lung on computed tomography of the chest. Most DCLD diseases are rare, although they might resemble common diseases such as emphysema and bronchiectasis. Main causes of DCLD include lymphangioleiomyomatosis, Birt–Hogg–Dubé syndrome, pulmonary Langerhans cell histiocytosis, lymphoid interstitial pneumonia, amyloidosis, light-chain deposition disease, Sjögren syndrome, and primary or metastatic neoplasm. We discuss clinical factors that are helpful in the differential diagnosis of DCLDsuch as sex and age, symptoms and signs, extrapulmonary presentations, cigarette smoking, and family history. Investigations for DCLD include high-resolution computed tomography, biochemical and histopathological studies, genetic tests, pulmonary function tests, and bronchoscopic and video-assisted thoracoscopic biopsies. A proposed diagnostic algorithm would enhance ease of diagnosing most cases of DCLD.

Note

Kai-Feng Xu and Ruie Feng contributed to this work equally.


 
  • References

  • 1 Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008; 246 (3) 697-722
  • 2 Johnson SR, Cordier JF, Lazor R , et al. Review Panel of the ERS LAM Task Force. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010; 35 (1) 14-26
  • 3 Gupta N, Vassallo R, Wikenheiser-Brokamp KA, McCormack FX. Diffuse cystic lung disease. Part I. Am J Respir Crit Care Med 2015; 191 (12) 1354-1366
  • 4 Ryu JH, Tian X, Baqir M, Xu K. Diffuse cystic lung diseases. Front Med 2013; 7 (3) 316-327
  • 5 Gupta N, Vassallo R, Wikenheiser-Brokamp KA, McCormack FX. Diffuse cystic lung disease. Part II. Am J Respir Crit Care Med 2015; 192 (1) 17-29
  • 6 Ryu JH, Sykes AM, Lee AS, Burger CD. Cystic lung disease is not uncommon in men with tuberous sclerosis complex. Respir Med 2012; 106 (11) 1586-1590
  • 7 Ryu JH, Moss J, Beck GJ , et al; NHLBI LAM Registry Group. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006; 173 (1) 105-111
  • 8 Hagaman JT, Schauer DP, McCormack FX, Kinder BW. Screening for lymphangioleiomyomatosis by high-resolution computed tomography in young, nonsmoking women presenting with spontaneous pneumothorax is cost-effective. Am J Respir Crit Care Med 2010; 181 (12) 1376-1382
  • 9 Mendez JL, Nadrous HF, Vassallo R, Decker PA, Ryu JH. Pneumothorax in pulmonary Langerhans cell histiocytosis. Chest 2004; 125 (3) 1028-1032
  • 10 Schmidt LS, Nickerson ML, Warren MB , et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet 2005; 76 (6) 1023-1033
  • 11 McCormack FX, Travis WD, Colby TV, Henske EP, Moss J. Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med 2012; 186 (12) 1210-1212
  • 12 Dal Sasso AA, Belém LC, Zanetti G , et al. Birt-Hogg-Dubé syndrome. State-of-the-art review with emphasis on pulmonary involvement. Respir Med 2015; 109 (3) 289-296
  • 13 Northrup H, Krueger DA ; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49 (4) 243-254
  • 14 Ren HZ, Zhu CC, Yang C , et al. Mutation analysis of the FLCN gene in Chinese patients with sporadic and familial isolated primary spontaneous pneumothorax. Clin Genet 2008; 74 (2) 178-183
  • 15 Kunogi M, Kurihara M, Ikegami TS , et al. Clinical and genetic spectrum of Birt-Hogg-Dube syndrome patients in whom pneumothorax and/or multiple lung cysts are the presenting feature. J Med Genet 2010; 47 (4) 281-287
  • 16 Tobino K, Gunji Y, Kurihara M , et al. Characteristics of pulmonary cysts in Birt-Hogg-Dubé syndrome: thin-section CT findings of the chest in 12 patients. Eur J Radiol 2011; 77 (3) 403-409
  • 17 Egashira R, Kondo T, Hirai T , et al. CT findings of thoracic manifestations of primary Sjögren syndrome: radiologic-pathologic correlation. Radiographics 2013; 33 (7) 1933-1949
  • 18 Lohrmann C, Uhl M, Warnatz K , et al. High-resolution CT imaging of the lung for patients with primary Sjogren's syndrome. Eur J Radiol 2004; 52 (2) 137-143
  • 19 Shi JH, Liu HR, Xu WB , et al. Pulmonary manifestations of Sjögren's syndrome. Respiration 2009; 78 (4) 377-386
  • 20 Baqir M, Kluka EM, Aubry MC , et al. Amyloid-associated cystic lung disease in primary Sjögren's syndrome. Respir Med 2013; 107 (4) 616-621
  • 21 Ozer Simsek Z, Oymak FS, Tutar N, Canoz O, Demir R. A rare cause of diffuse parenchymal lung disease together with granulomatous reaction: pulmonary amyloidosis. Case Rep Pulmonol 2013; 2013: 837190
  • 22 Lantuejoul S, Moulai N, Quetant S , et al. Unusual cystic presentation of pulmonary nodular amyloidosis associated with MALT-type lymphoma. Eur Respir J 2007; 30 (3) 589-592
  • 23 Kang LY, Ho SP, Chou YP. Primary thymic mucosa-associated lymphoid tissue lymphoma with multiple thin walled lung cysts: case report and literature review. Chin J Cancer Res 2013; 25 (3) 354-357
  • 24 Suri HS, Yi ES, Nowakowski GS, Vassallo R. Pulmonary Langerhans cell histiocytosis. Orphanet J Rare Dis 2012; 7: 16
  • 25 Avila NA, Dwyer AJ, Rabel A, Moss J. Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features. Radiology 2007; 242 (1) 277-285
  • 26 Xu KF, Zhang W, Liu H. Miliary pulmonary lymphangioleiomyomatosis. Am J Respir Crit Care Med 2013; 187 (8) e15
  • 27 Xu KF, Zhang P, Tian X , et al. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM). Respir Med 2013; 107 (2) 263-268
  • 28 Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 2009; 135 (5) 1293-1300
  • 29 Seyama K, Kumasaka T, Souma S , et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol 2006; 4 (3) 143-152
  • 30 Young LR, Vandyke R, Gulleman PM , et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 2010; 138 (3) 674-681
  • 31 McCormack FX, Inoue Y, Moss J , et al. National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364 (17) 1595-1606
  • 32 Young L, Lee HS, Inoue Y , et al. MILES Trial Group. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med 2013; 1 (6) 445-452
  • 33 Liu Z, Xu KF, Hu C , et al. Use of whole-exome sequencing for the diagnosis of atypical Birt-Hogg-Dubé syndrome. J Genet Genomics 2014; 41 (8) 449-451
  • 34 Ramachandra CJ, Mehta A, Guo KW, Wong P, Tan JL, Shim W. Molecular pathogenesis of Marfan syndrome. Int J Cardiol 2015; 187: 585-591
  • 35 Abramowicz A, Gos M. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease. Dev Period Med 2014; 18 (3) 297-306
  • 36 Foreman MG, Campos M, Celedón JC. Genes and chronic obstructive pulmonary disease. Med Clin North Am 2012; 96 (4) 699-711
  • 37 Callewaert B, Su CT, Van Damme T , et al. Comprehensive clinical and molecular analysis of 12 families with type 1 recessive cutis laxa. Hum Mutat 2013; 34 (1) 111-121
  • 38 Callewaert B, Renard M, Hucthagowder V , et al. New insights into the pathogenesis of autosomal-dominant cutis laxa with report of five ELN mutations. Hum Mutat 2011; 32 (4) 445-455
  • 39 Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 2000; 97 (11) 6085-6090
  • 40 Crooks DM, Pacheco-Rodriguez G, DeCastro RM , et al. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 2004; 101 (50) 17462-17467
  • 41 Kobayashi M, Tojo A. The BRAF-V600E mutation in circulating cell-free DNA is a promising biomarker of high-risk adult Langerhans cell histiocytosis. Blood 2014; 124 (16) 2610-2611
  • 42 Yousem SA, Dacic S, Nikiforov YE, Nikiforova M. Pulmonary Langerhans cell histiocytosis: profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations. Chest 2013; 143 (6) 1679-1684
  • 43 Brown NA, Furtado LV, Betz BL , et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood 2014; 124 (10) 1655-1658
  • 44 Nelson DS, van Halteren A, Quispel WT , et al. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer 2015; 54 (6) 361-368
  • 45 Nelson DS, Quispel W, Badalian-Very G , et al. Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood 2014; 123 (20) 3152-3155
  • 46 Meraj R, Wikenheiser-Brokamp KA, Young LR, Byrnes S, McCormack FX. Utility of transbronchial biopsy in the diagnosis of lymphangioleiomyomatosis. Front Med 2012; 6 (4) 395-405
  • 47 Cai X, Pacheco-Rodriguez G, Fan QY , et al. Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis. Am J Respir Crit Care Med 2010; 182 (11) 1410-1418
  • 48 Xu KF, Lo BH. Lymphangioleiomyomatosis: differential diagnosis and optimal management. Ther Clin Risk Manag 2014; 10: 691-700